BDSX · Biodesix Inc
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Sep 15, 2025; bars on opposite sides are not compared.
The closing range begins at the captured split on Sep 15, 2025.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Biodesix delivered 34% Q2 revenue growth to $26.9M, 42% diagnostic testing growth, 82% gross margins (+200 bps YoY), and a 56% Adjusted EBITDA loss improvement, while reiterating full-year 2026 revenue guidance of $108–114M (midpoint ~25% growth). Development Services revenue declined year-over-year, and management cautioned that further gross margin upside is limited and biopharma services revenue is lumpy.
- + Q2 revenue grew 34% YoY to $26.9M, with Diagnostic Testing up 42% on 38% volume growth
- + Gross margin reached 82%, a 200 bps YoY improvement, marking a fifth consecutive quarter at or above 80%
- + Net loss improved 37% YoY to $7.3M and cash burn (ex-ATM) improved 70% to $2.1M, with $30M cash on hand
- + Reiterated previously raised full-year 2026 revenue guidance of $108–114M, midpoint ~25% growth, with continued Adjusted EBITDA progress expected
- − Development Services revenue declined to $1.5M from $2.1M YoY due to project timing
- − Management indicated limited further gross margin upside beyond the ~80% range
- − Management cautioned that biopharma/Development Services revenue can be seasonal and lumpy, creating execution risk against guidance
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BDSX
this stock
Biodesix Inc
|
$276.23M | +285.0% | +24.1% | — | 1.4% |
|
TMO
Thermo Fisher Scientific Inc.
|
$226.94B | +5.9% | +14.5% | 33.0 | 1.3% |
|
DHR
Danaher Corp /De/
|
$145.98B | -9.3% | +8.5% | 36.8 | 1.2% |
|
NTRA
Natera, Inc.
|
$47.31B | +43.3% | -2.8% | — | 3.0% |
|
IQV
Iqvia Holdings Inc.
|
$44.69B | +18.8% | +41.6% | 33.3 | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Sep 15, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BDSX | -2.4% | +11.4% | +51.4% | -0.6% | +285.0% |
| SPY | +0.1% | -0.4% | +15.1% | +0.4% | +12.9% |
| vs SPY | -2.5% | +11.8% | +36.3% | -1.0% | +272.1% |